36 results about "Renal cancers" patented technology

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

Device and methods for detection of kidney cancer using urine samples are disclosed herein. The device and methods enable isolation and quantification of kidney tumor cells in urine samples from a subject in need thereof.

The invention relates to a tumor-related DNA methylation marker combination, which is selected from at least one of the following: a target sequence as shown in SEQ ID NO: 1-SEQ ID NO: 10, a nucleic acid fragment with the length of at least 15 oligonucleotides or a complementary nucleic acid fragment thereof, and the nucleic acid fragment comprises at least one methylation site indicated by CG. The invention also relates to a detection kit for the methylation marker combination. According to the invention, the combination of the co-methylation states of a plurality of specific methylation regions is used for distinguishing and analyzing the occurrence of tumors, especially kidney cancer, the specific methylation combination has high sensitivity for distinguishing the occurrence of kidney cancer, and the detection method is simple, convenient and feasible. The primer pair combination of the kit overcomes the defect of false positive caused by detection mismatch of a single methylation site in the aspect of primer sequence design, and the interaction between a plurality of methylation biomarker primers and probe pair combinations is considered.

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

The invention relates to a novel cyclopeptide medicine PT-C10 with anti-tumor activity. The amino acid sequence of the novel cyclopeptide medicine PT-C10 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C10 to the 786-O kidney cancer cells is 42.23 mu M, and the IC50 of the cyclopeptide PT-C10 to the A498 kidney cancer cells is 15.53 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and the A498 and shows obvious killing efficacy. The cyclic peptide PT-C10 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

This invention belongs to the field of pharmaceutical technology and specifically relates to the use of apigenin derivatives in the preparation of anti-tumor drugs. The structure of the apigenin derivative is shown below: wherein the groups are defined as described in the specification. The compounds of this invention effectively inhibit the proliferation of renal cancer Caki-1 cells, human gastric cancer cells SNU-5, lung cancer cells, and human colon cancer cells HCT 116 in vitro. They also exhibit good inhibitory activity against renal cancer Caki-1 cells in vivo, demonstrating promising application prospects.

The present invention relates to the use of sodium pentaborate pentahydrate enriched with boron isotope (10B, 11B) as a chemotherapeutic agent thanks to its anticarcinogenic effect on renal cancer. As a result of the experimental studies performed within the scope of the invention, it has been shown that while the number of renal cancer cells decreased by 50%, this effect occurs by arresting the cell cycle and slowing down cell proliferation, therefore sodium pentaborate pentahydrate enriched with boron isotope can be used as a chemotherapeutic agent in cancer treatment.

The invention discloses a marker group for screening and diagnosing kidney cancer and application of the marker group, and belongs to the technical field of molecular biology. The marker group comprises at least four of polypeptides as shown in sequences SEQ ID NO. 1 to 38. The marker combination constructed by the invention has more excellent sensitivity and specificity when being used for auxiliary diagnosis and early screening of kidney cancer. The auxiliary diagnosis result of the kit is superior to that of imaging examination which is one of main schemes for clinical diagnosis of kidney tumors at present, and CT is enhanced (the sensitivity and the specificity are 78.67% and 87.88% respectively). The early screening result is superior to that of a high-frequency color Doppler ultrasonic instrument (the diagnosis sensitivity is 94.87%, and the specificity is 80%) which is applied to routine examination of the abdomen in physical examination at present; the sensitivity is 62.9%, and the specificity is 87.0%.

The invention provides a kidney cancer risk grade analysis method based on deep learning. The method comprises the following steps: acquiring multi-modal medical data of a patient and preprocessing the multi-modal medical data to construct a training sample set; training a risk level prediction model by using the sample set until a preset condition is met; inputting data of a to-be-detected patient into the trained model to obtain a predicted risk level, if a low risk threshold is met, suggesting conventional follow-up visit, otherwise, optimizing treatment scheme parameters by adopting a multi-objective optimization algorithm, evaluating the risk level of each scheme through the model, and calculating a fitness function value in combination with a side effect score and a treatment cost; and finally outputting an optimal scheme as a clinical intervention basis. According to the invention, accurate prediction of the risk level of the kidney cancer can be realized, and the accuracy of clinical decision and the benefit-cost ratio of a treatment scheme are improved.

The invention relates to a novel cyclopeptide drug PT-C07 with antitumor activity. The amino acid sequence of the novel cyclopeptide drug PT-C07 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C07 to the 786-O kidney cancer cells is 77.53 mu M, and the IC50 of the cyclopeptide PT-C07 to the A498 kidney cancer cells is 67.06 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The cyclic peptide PT-C07 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The application discloses a chimeric antigen receptor targeting CA9 and application thereof, and belongs to the technical field of biological medicine. The chimeric antigen receptor targeting CA9 comprises a CD8 alpha leader signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane domain and a CD3 zeta intracellular costimulatory signaling domain. The application adopts the anti-CA9 single-chain variable fragment as an antigen binding domain to construct a chimeric antigen receptor (CAR) molecule, and the macrophage expressing the anti-CA9 CAR can realize specific targeting and phagocytosis and killing of CA9 positive renal cancer cells, the constructed lipid nanoparticle delivery system can effectively carry a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the constructed hydrogel-liposome combined drug delivery system has the performances of relieving toxic and side effects, controllable release and hemostasis.

The invention belongs to the field of chemical synthesis, and particularly relates to a small molecule compound K-H03 with an anti-tumor effect and application of the small molecule compound K-H03 in anti-tumor drugs, and the small molecule compound has a structural formula as shown in a formula I. The compound has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a method for preparing the compound and application of the compound in preparation of antitumor drugs. Experimental results show that the IC50 of the K-H03 to the 786-O kidney cancer cells is 203.0 [mu] M, and the IC50 of the K-H03 to the A498 kidney cancer cells is 175.5 [mu] M, which indicates that the K-H03 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The K-H03 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The invention discloses a diagnostic marker for the drug resistance of kidney cancer sunitinib. The diagnostic marker for the drug resistance of kidney cancer sunitinib is selected from a group consisting of histone acetyltransferase KAT2A. The invention further discloses a kit for detecting the sunitinib drug resistance of the kidney cancer. The kit comprises a reagent for detecting the expression quantity of KAT2A. The KAT2A provided by the invention is used as a renal cancer sunitinib drug resistance diagnosis marker, has good specificity and high sensitivity, provides a new diagnosis and treatment means for renal cancer sunitinib drug resistance, is beneficial to drug resistance monitoring and avoids further invalid treatment, and has a good medical conversion prospect.

The application discloses a marker group for kidney cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-38.The marker group constructed by the application has more excellent sensitivity and specificity when used for the auxiliary diagnosis and early screening of kidney cancer.The auxiliary diagnosis result is better than that of one of main current clinical diagnosis schemes for kidney tumors, i.e., imaging examination, and enhanced CT (sensitivity and specificity are 78.67% and 87.88%, respectively).The early screening result is better than that of a high-frequency color Doppler ultrasound instrument (diagnostic sensitivity is 94.87%, and specificity is 80%) applied to the routine examination of the abdomen in a health examination; and multi-gene methylation combined analysis (sensitivity is 62.9%, and specificity is 87.0%).

The invention discloses a classification method for cross-modal renal cancer pathology upgrading based on a double-input fusion network, and the method comprises the steps: building the double-input fusion network which comprises a Bottom branch, a Upper branch and a feature fusion module, and obtaining the nonlinear enhanced high-level semantic features of an original renal cancer CT image through the original renal cancer CT image and the Upper branch; meanwhile, through the kidney cancer CT image subjected to image enhancement and Bottom branches, nonlinear enhancement high-level semantic features of the enhanced kidney cancer CT image are obtained, and finally classification of the kidney cancer CT image is completed through a feature fusion module. According to the double-input fusion network, cross-modal classification of the images can be automatically and efficiently achieved, when complex images are processed, the capturing capacity of fine-grained features is high, the calculation cost is low, the accuracy of the classification result of the images is high, and the double-input fusion network has great significance in achieving kidney cancer pathology upgrading diagnosis.

The present invention provides a pazopanib-resistant renal clear cell carcinoma cell line, a construction method, and an application thereof. The deposit number of the renal clear cell carcinoma cell line is GDMCC NO: 65811. The renal clear cell carcinoma cell line is a 786-O pazopanib-resistant cell line. The cell line is constructed by inducing the proliferation of renal cancer cells 786-O in the presence of pazopanib by gradually increasing the concentration of pazopanib. Through comprehensive transcriptome analysis, the molecular mechanism of drug resistance is interpreted, providing a new treatment strategy for clinical treatment of drug resistance.

The application belongs to the technical field of medicines, and particularly relates to application of an eight-membered selenium-containing benzazepine compound in preparation of an antitumor drug. The eight-membered selenium-containing benzazepine compound is prepared by an electrochemical method, and the reaction condition is mild and the operation is simple. The compound has certain antitumor and antibacterial activities, and particularly shows good inhibition on renal cancer cells 769-P and A498, and has a good application prospect.

The present disclosure provides methods for treating mesonephric cancers in a subject in need thereof comprising administering a RAF / MEK inhibitor in combination with a FAK inhibitor.

The invention belongs to the technical field of biomedicine, and relates to a methylation characteristic data detection method and a detection kit. The method comprises the following steps: extracting genome DNA from a tissue sample; performing high-throughput detection on the methylation level of the CpG site in the genome DNA to obtain a detection result; constructing a methylation characteristic analysis model based on the methylation state of the CpG site in the detection result; generating methylation feature data of the tissue sample through the model; the methylation characteristic data is used for detecting a kidney cancer specific DNA methylation marker associated with the abnormal tricarboxylic acid cycle metabolism. Through integration of multi-omics data and strict screening standards, detection of needle biopsy and surgical resection samples is supported, compatibility is high, generation and analysis of methylation data are focused, and disease diagnosis or treatment is avoided.

The present disclosure relates generally to compounds of Formulae (1-A), (1-B1), (1-C) and ((1-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, prostate, or ovarian cancer.

The invention provides a kidney cancer early diagnosis and detection marker combination, application and a kit, and relates to the technical field of biological medicine.In the kidney cancer early diagnosis and detection marker combination, an early kidney cancer marker database is constructed through mass spectrum-based serum proteome analysis, comprehensive marker screening and verification are performed through mass spectrum, machine learning is performed, multiple marker combinations are screened, and the kidney cancer early diagnosis and detection marker combination is obtained. And evaluation is carried out through the internal queue and the external queue to distinguish the early kidney cancer. The biomarkers (RCC-5) of the five proteins are used for distinguishing RCC patients from normal people (RCC vs.NC), and the accuracy rate reaches 95.23%.

The invention provides a metabolic marker composition for distinguishing healthy kidney cancer from early kidney cancer. According to an analysis method based on urine metabonomics, a diagnosis model capable of accurately distinguishing healthy people from early-stage kidney cancer patients is constructed by detecting a specific metabolic marker combination and combining a machine learning algorithm. The model can noninvasively discriminate the early-stage kidney cancer in a high-sensitivity and high-specificity manner, and breaks through the limitation of an existing clinical detection method. The method disclosed by the invention has the advantages of noninvasive property, simple and convenient sampling and the like, is suitable for large-scale population screening, is particularly beneficial to popularization of early-stage kidney cancer risk screening in remote areas deficient in medical resources, and provides support for early-stage noninvasive diagnosis and effective prevention and control of kidney cancer.

The invention provides application of K46 lactic acid of AARS2 mediated ULK1 as a target spot in preparation of an anti-kidney cancer product, so that the K46 lactic acid of the AARS2 mediated ULK1 as the target spot can be used for preparing the anti-kidney cancer product. The use comprises partial or complete knockout of AARS2 and / or ULK1 genes; the AARS2 protein activity is inhibited; the K46 gene of the ULK1 is subjected to specific mutation; the invention relates to a cell penetrating peptide aiming at a ULK1 K46 site and other methods. And inhibiting the expression of AARS2 and / or controlling the K46 lactylation level of ULK1 to play a role in resisting kidney cancer.

The present invention provides: a method of predicting the anticancer drug resistance and / or prognosis in a kidney cancer patient, said method comprising a step for evaluating the expression of Largen in the kidney cancer tissue of a subject and a step for comparing the Largen expression level in the kidney cancer tissue of the subject with a control; and a method of screening an anti-kidney cancer substance, said method comprising (1) a step for contacting a test substance with kidney cancer cells that express Largen, (2) a step for measuring the expression amount of Largen in the kidney cancer cells, and (3) a step for comparing the thus determined expression amount of Largen with the expression amount of Largen in the kidney cancer cells that have not been contacted with the test substance and thus selecting a test substance that lowers the expression amount.

A combination drug for treating kidney caner, said combination drug comprising a tyrosine kinase inhibitor combined with a dipeptidyl peptidase 4 inhibitor; and a therapeutic effect enhancer for a tyrosine kinase inhibitor, said therapeutic effect enhancer comprising a dipeptidyl peptidase 4 inhibitor and enhancing the therapeutic effect of the tyrosine kinase inhibitor on kidney cancer.

The invention provides a blood metabolism marker combination for distinguishing health and kidney cancer and application of the blood metabolism marker combination. According to the metabolic marker combination for screening and diagnosing the kidney cancer, whether a patient suffers from the kidney cancer or not is judged by detecting the metabolic marker combination in a blood sample, the method has high sensitivity and specificity, accurate screening of the kidney cancer can be achieved, and important help is provided for prevention of the kidney cancer and reduction of the morbidity. The kidney cancer diagnosis model with high sensitivity and specificity is constructed based on the metabonomics data of plasma, the method is convenient and economical, samples are convenient to obtain, and the method is more suitable for large-scale population screening and regular tracking in areas with shortage of medical resources.

The invention relates to the field of biological medicine manufacturing, in particular to a monoclonal antibody capable of being specifically combined with carbonic anhydrase IX and application of the monoclonal antibody in urinary disease treatment. The monoclonal antibody is Y03, a heavy chain variable region of the monoclonal antibody comprises CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, CDR2 of which the amino acid sequence is shown as SEQ ID NO: 3 and CDR3 of which the amino acid sequence is shown as SEQ ID NO: 4, and a light chain variable region of the monoclonal antibody comprises CDR1 of which the amino acid sequence is shown as SEQ ID NO: 6, CDR2 of which the amino acid sequence is shown as SEQ ID NO: 7 and CDR3 of which the amino acid sequence is shown as SEQ ID NO: 8. The monoclonal antibody Y03 is high in affinity and good in specificity, has potential value in treatment of urinary diseases, for example, has good killing activity on solid tumor cells such as kidney cancer cells, and can be applied to early diagnosis and targeted therapy of CAIX antigen expression tumors including kidney cancer.

The application discloses application of TPM3P9 protein and RBM4 protein in kidney cancer. The application finds that high expression of RBM4 indicates better prognosis of a kidney cancer patient, low expression of TPM3P9 and high expression of RBM4 are the best for the prognosis of a patient, therefore, the RBM4 protein or the RBM4 protein and the TPM3P9 protein can be used together as a kidney cancer clinical diagnosis or prognosis biomarker. The application also finds through experiments that the proliferation and growth of kidney cancer cells can be regulated by regulating the expression amount of the TPM3P9 protein, therefore, the RBM4 protein and the TPM3P9 protein can be used together for developing a medicine for treating kidney cancer or proliferation and growth of kidney cancer cells.

The invention discloses a targeted drug for sensitizing Ilismos-copper complex induced copper death and application thereof, can sensitize copper death induced by tumor cells to Cu (II)-Elesclomol, and realizes high-efficiency and low-toxicity treatment of renal cell carcinoma in combination with a c-Met targeting technology, and particularly relates to a targeted drug for sensitizing Ilismos-copper complex induced copper death and application thereof. According to the targeted drug for sensitizing the ilisterim-copper complex to induce copper death, mesoporous silica serves as a nano-carrier, the surface of the carrier is modified with specific polypeptide of a targeted kidney cancer cell c-Met receptor, and taurine and a Cu (II)-Elesclomol complex are jointly loaded in an internal pore channel of the carrier.